RAS Inhibitor Is Not Associated With Cardiovascular Benefits in Patients Undergoing Hemodialysis in Japan.

about

RAS Inhibitor Is Not Associated With Cardiovascular Benefits in Patients Undergoing Hemodialysis in Japan.

Item

http://www.wikidata.org/entity/Q40073611

description

2017 nî lūn-bûn

@nan

2017年の論文

@ja

2017年学术文章

@wuu

2017年学术文章

@zh-cn

2017年学术文章

@zh-hans

2017年学术文章

@zh-my

2017年学术文章

@zh-sg

2017年學術文章

@yue

2017年學術文章

@zh

2017年學術文章

@zh-hant

name

RAS Inhibitor Is Not Associate ...... ergoing Hemodialysis in Japan.

@en

type

Item

label

RAS Inhibitor Is Not Associate ...... ergoing Hemodialysis in Japan.

@en

prefLabel

RAS Inhibitor Is Not Associate ...... ergoing Hemodialysis in Japan.

@en

P1476

RAS Inhibitor Is Not Associate ...... dergoing Hemodialysis in Japan

@en

P2093

Shunichi Fukuhara

http://www.w3.org/2001/XMLSchema#string

Tadao Akizawa

http://www.w3.org/2001/XMLSchema#string

Yoshihiro Onishi

http://www.w3.org/2001/XMLSchema#string

P2860

Effects of an angiotensin-converting-enzyme inhibitor, ramipril, on cardiovascular events in high-risk patients

Long-term ACE-inhibitor therapy in patients with heart failure or left-ventricular dysfunction: a systematic overview of data from individual patients. ACE-Inhibitor Myocardial Infarction Collaborative Group.

Effect of lowering blood pressure on cardiovascular events and mortality in patients on dialysis: a systematic review and meta-analysis of randomised controlled trials

Effects of ACE inhibitors, calcium antagonists, and other blood-pressure-lowering drugs: results of prospectively designed overviews of randomised trials. Blood Pressure Lowering Treatment Trialists' Collaboration.

Rosuvastatin and cardiovascular events in patients undergoing hemodialysis.

Kidney disease as a risk factor for development of cardiovascular disease: a statement from the American Heart Association Councils on Kidney in Cardiovascular Disease, High Blood Pressure Research, Clinical Cardiology, and Epidemiology and Preventi

Effects of different blood-pressure-lowering regimens on major cardiovascular events: results of prospectively-designed overviews of randomised trials.

Cardiovascular morbidity and mortality in the Losartan Intervention For Endpoint reduction in hypertension study (LIFE): a randomised trial against atenolol.

Renin-angiotensin system blockade and the risk of hyperkalemia in chronic hemodialysis patients.

Efficacy of perindopril in reduction of cardiovascular events among patients with stable coronary artery disease: randomised, double-blind, placebo-controlled, multicentre trial (the EUROPA study).

P304

326-333

http://www.w3.org/2001/XMLSchema#string

P31

scholarly article

P356

10.1111/1744-9987.12540

http://www.w3.org/2001/XMLSchema#string

P433

http://www.w3.org/2001/XMLSchema#string

P478

http://www.w3.org/2001/XMLSchema#string

P50

Hiroaki Ogata

Shingo Fukuma

Masahide Mizobuchi

P577

2017-08-01T00:00:00Z

http://www.w3.org/2001/XMLSchema#dateTime

P698

28834360

http://www.w3.org/2001/XMLSchema#string